Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:
-How Dupixent is changing the game for CSU and why dermatologists are leading the charge
-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients
-How we explain to CSU patients that they don’t need allergy testing!
-Clinical pearls for work-up, navigating treatment guidelines, safety, and access
Perfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.
Hit play and stay ahead on the cutting edge of CSU care!
1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound
2. Remibrutinib in Chronic Spontaneous Urticaria
3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials